Information från ABG Sundal Collier

Här finner du information kring börsens mindre och medelstora bolag. Avsändare är ABG Sundal Collier, innehållet är inte skapat av placera.nu:s redaktion.

« Tillbaka

Medicover - A "charmingly aggressive" CEO

26 augusti 2025

<a id="bm-comp-59995928-8387-4bad-bcbe-0fb9e5b85864" name="bm-comp-59995928-8387-4bad-bcbe-0fb9e5b85864" class="BMCustomAnchor"></a><table><tr><td bm-component-id="59995928-8387-4bad-bcbe-0fb9e5b85864" style="vertical-align: top; width:100.000000%;"><ul><li>Scale and presence underpin growth and margin expansion</li><li>Sharper execution on cross-segment synergies</li><li>Trading at ~13x '25e EV/EBITDA</li></ul></td></tr></table><a id="bm-comp-7f9ec0e2-9956-42ca-ae8e-44ba78678a83" name="bm-comp-7f9ec0e2-9956-42ca-ae8e-44ba78678a83" class="BMCustomAnchor"></a><table><tr><td bm-component-id="7f9ec0e2-9956-42ca-ae8e-44ba78678a83" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3"><strong>Presence matters</strong></h3><p>We hosted Medicover&#8217;s CEO John Stubbington and CFO Anand Patel for lunch earlier today. The discussion centred on how Medicover is positioned to continue delivering strong revenue and earnings growth. At the core of the strategy is the company&#8217;s deep and growing presence across its core markets: Poland, Germany, Romania, and India (illustration from Medicover included further down). The footprint has expanded steadily over the past years, with more members, clinics, hospitals, labs, BDPs, fitness clubs, and medical spaces, which reinforces Medicover&#8217;s ambition to be the go-to provider in each market. Following the lunch, we leave our estimates intact and continue to forecast annual organic sales growth of 15% for '25e-'27e, with adj. EBITDAaL margins improving from 10.9% in '25e to 11.5% in '27e, supported by increased capacity utilisation, maturing units, and a growing share of higher-margin business.</p><h3 class="bm-h3"><strong>Strategic clarity and growing synergy potential</strong></h3><p>Though John Stubbington is new in the CEO role, he&#8217;s been with Medicover since 2010, serving as COO of Healthcare Services. His second appearance at ABGSC showed increased confidence and a clear strategic message: continue in the same direction, but with a sharper focus on group-wide synergies. The integration of M&amp;A teams and shared resources across the two segments signals a shift towards more coordinated execution. Stubbington described himself as &#8220;charmingly aggressive&#8221;, and we see this reflected in the ambition to unlock further value through segment collaboration and smarter capital allocation. While leverage is currently elevated, Medicover has made it clear that the M&amp;A pipeline remains active, with the intention to accelerate once balance sheet flexibility improves.</p><h3 class="bm-h3"><strong>Healthy structural drivers</strong></h3><p>Medicover&#8217;s growth case remains supported by several structural tailwinds: rising healthcare spending, an ageing population, unmet demand in its core markets, and a broad service offering built around a strong brand. The India IPO process appears to be progressing as planned, despite slower growth in Q1'25 delaying it somewhat, with potential updates expected over the next 6&#8211;12 months. On current estimates, Medicover trades at ~13x &#8216;25e EV/EBITDA. Our fair value range of SEK 220-300 corresponds to a &#8216;25e EV/EBITDA of 11x&#8211;14x.</p></td></tr></table><a id="bm-comp-378c43e3-724a-48cf-9c9d-b500662aed70" name="bm-comp-378c43e3-724a-48cf-9c9d-b500662aed70" class="BMCustomAnchor"></a><table><tr><td bm-component-id="378c43e3-724a-48cf-9c9d-b500662aed70" style="vertical-align: top; width:100.000000%;"><table id="bm-img-4fe47247-f421-416d-b141-b39e33ce34d4" class="bm-img-table xslt-img-empty xslt-img-include"><tr><td class="xslt-img-caption">Medicover illustration of local presence in core markets</td></tr><tr><td><img bm-img-encrypt="4fe47247-f421-416d-b141-b39e33ce34d4" bm-img-original-height="796" bm-img-original-width="1682" bm-img-svg="image:image_upload/89987_35841e80-1ef9-421e-a923-32b96b34ba4d.svg" bm-img-width-hint="100%" id="bm-id-4fe47247-f421-416d-b141-b39e33ce34d4" src="https://abgsc.bluematrix.com/images/image_upload/89987_35841e80-1ef9-421e-a923-32b96b34ba4d_732.png" svg="/nas/web/clients/abgsc/images/image_upload/89987_35841e80-1ef9-421e-a923-32b96b34ba4d.svg" width="727" alt="" title="" /></td></tr><tr><td class="xslt-img-source">Source: Company data</td></tr></table></td></tr></table>

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2025-08-27 Inission - Q2 likely marked the R12m EBITA trough Inission Analys
2025-08-27 BTS Group - North America turnaround in focus BTS Group Analys
2025-08-27 INVISIO - Positive outlook comments from peers INVISIO Analys
2025-08-27 Eolus Vind - Profitability facing headwinds Eolus Vind Analys
2025-08-27 Inission - Enedo the culprit of weaker Q2 EBITA Inission Analys
2025-08-26 Medicover - A "charmingly aggressive" CEO Medicover Analys
2025-08-26 Gentoo Media - Top-line challenges remain Gentoo Media Analys
2025-08-26 Catella - Ready to spring into action Catella Analys
2025-08-26 Impact Coatings - Preparing for market recovery Impact Coat.. Analys
2025-08-26 Ogunsen - Set to grow once the market improves Ogunsen Analys
2025-08-26 Gentoo Media - Soft Q2 and FY guidance downgrade Gentoo Media Analys
2025-08-26 Eolus Vind - Profitability impacted by project delay Eolus Vind Analys
2025-08-25 Ascelia Pharma - Ready for a decisive year Ascelia Pharma Analys
2025-08-24 I-tech - A pause, not a stop I-tech Analys
2025-08-24 Generic - Communication flows, margin grows Generic Analys
2025-08-24 Clavister - Scaling towards positive EBIT Clavister Analys
2025-08-22 Byggmästaren - Several promising developments Byggmästaren Analys
2025-08-22 Ogunsen - Sales beat but pressured profitability Ogunsen Analys
2025-08-22 Impact Coatings - Continued cautious market Impact Coat.. Analys
2025-08-22 I-tech - Big Q2 miss halts sales growth I-tech Analys